The global robotic biopsy devices market has reached a valuation of USD 440.2 million in 2023 and is projected to grow at a CAGR of 9.3% over the forecast period. With robotic biopsy systems leading the market, these devices accounted for approximately 59.8% of the total market share in 2023.
The increasing demand for minimally invasive procedures and the need for precise and accurate diagnostics are driving the growth of the robotic biopsy devices market. These advanced systems enhance the efficiency of biopsy procedures, reduce patient discomfort, and improve overall outcomes, making them an essential tool in modern medical practice.
As healthcare providers continue to adopt innovative technologies to enhance diagnostic capabilities, the market for robotic biopsy devices is expected to expand significantly. By the end of the forecast period in 2033, the market is anticipated to reach a valuation of around USD 1,072.3 million.
Key stakeholders in the healthcare sector are encouraged to stay informed about advancements in robotic biopsy technology, as these innovations are set to transform the landscape of diagnostic procedures.
The remarkable growth of the robotic biopsy devices industry can be attributed to the relentless pursuit of innovation and cutting-edge advancements in robotic biopsy systems. In 2023, these systems held a commanding 59.8% market share, solidifying their position as a game-changer in the global market. The incorporation of state-of-the-art robotic systems has significantly raised the bar for neurosurgical procedures, delivering unrivaled precision and improved patient outcomes.
The market for Robotic Biopsy Devices is anticipated to grow at a fast pace over the projected years due to the rising need for safe and effective minimally invasive procedures and the growing use of automated systems in the healthcare sector. It can be further attributed to the rapid transformation of conventional healthcare systems to integrated digital technology.
Key Takeaways: Global Robotic Biopsy Devices Industry
- By product, the systems segment is expected to showcase high growth at a CAGR of 4% by the end of 2032.
- By application, the brain biopsy category is leading the Global Robotic Biopsy Devices Industry and is projected to exhibit a CAGR of 3% during the forecast period.
- By end user, hospitals held around 5% of the Global Robotic Biopsy Devices Industry share in 2021.
- The U.S. currently dominates the North America Robotic Biopsy Devices market and it generated a share of about 8% in 2021.
- The U.K. is set to hold a share of nearly 2% in the Global Robotic Biopsy Devices Industry during the assessment period.
“Increasing use of automated technologies for surgical procedures and growing global burden of chronic diseases are expected to drive sales of Robotic Biopsy Devices,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Competition Landscape: Global Robotic Biopsy Devices Industry
The market for Robotic Biopsy Devices is oligopolistic, with the presence of a few established manufacturers. The product range of every player in the market varies as per the competitors’ licensed novel devices with unique applications. Key players are striving to gain regulatory authorizations for creating new medical devices, generating high product sales, and initiating marketing purposes.
- In October 2021, Medtronic reported that the Hugo robotic-assisted surgery (RAS) system had been granted the CE (Conformité Européenne) Mark, allowing for sales of the system across Europe.
Key Players
- Medtronic
- Renishaw plc
- iSYS Medizintechnik GmbH
- Mazor Robotics
- Biobot Surgical Pte Ltd
- Medrobotics
- Medtech SA
What Does the Global Robotic Biopsy Devices Industry Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the Global Robotic Biopsy Devices Industry in its latest study, presenting a historical demand assessment of 2012 to 2021 and projections for 2022 to 2032.
Global Robotic Biopsy Devices Industry Outlook by Category
By Product:
- Systems
- Instrument & Accessories
By Application:
- Brain Biopsy
- Lung Biopsy
- Prostate biopsy
- Others
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Academic & Research Institutes
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube